Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-7375 in Advanced KRAS G12D-Mutated NSCLC
NCT07659782Phase 2Recruiting
- Sponsor
- Verastem Oncology
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 3
01
Overview
A Phase 2 trial of GFH375 in non-small cell lung cancer (NSCLC), sponsored by Verastem Oncology. Started Jul 2026; status: recruiting.
02
Drugs
GFH375
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07659782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07659782.